Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
about
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Caplacizumab reduces the frequ ...... otic thrombocytopenic purpura.
@en
type
label
Caplacizumab reduces the frequ ...... otic thrombocytopenic purpura.
@en
prefLabel
Caplacizumab reduces the frequ ...... otic thrombocytopenic purpura.
@en
P2093
P2860
P356
P1476
Caplacizumab reduces the frequ ...... otic thrombocytopenic purpura.
@en
P2093
F Callewaert
H De Winter
R K Zeldin
S Cataland
P2860
P304
P356
10.1111/JTH.13716
P577
2017-04-26T00:00:00Z